In this case, using appropriate tools such as humanized monoclonal antibodies (hmAb) to programmed cell death receptor 1 (PD1), programmed cell death receptor ligand 1 (PDL1) or cytotoxic activated T lymphocyte 4 receptor (CTLA4), it is possible to reactivate the adaptive anti-tumor-specific immune response [7,8,9,10,11]. Here, CD274 is linked to neoplasm.